These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29579725)

  • 1. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
    Holt SR; Donroe JH; Cavallo DA; Tetrault JM
    Drug Alcohol Depend; 2018 May; 186():171-174. PubMed ID: 29579725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice.
    Donroe JH; Holt SR; O'Connor PG; Sukumar N; Tetrault JM
    Drug Alcohol Depend; 2017 Nov; 180():46-51. PubMed ID: 28866369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.
    Bagley SM; Cheng DM; Winter M; Alford DP; LaBelle C; Walley AY; Samet JH
    Drug Alcohol Depend; 2018 Nov; 192():245-249. PubMed ID: 30290291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of urinary naloxone levels in a single provider practice: a case study.
    Warrington JS; Booth K; Warrington GS; Francis-Fath S
    Addict Sci Clin Pract; 2020 Jan; 15(1):3. PubMed ID: 31941557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
    Suzuki J; Zinser J; Issa M; Rodriguez C
    Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
    Schottenfeld RS; Chawarski MC; Pakes JR; Pantalon MV; Carroll KM; Kosten TR
    Am J Psychiatry; 2005 Feb; 162(2):340-9. PubMed ID: 15677600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
    Accurso AJ; Lee JD; McNeely J
    J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in Buprenorphine- versus methadone-maintained patients.
    Schottenfeld RS; Pakes JR; Kosten TR
    J Nerv Ment Dis; 1998 Jan; 186(1):35-43. PubMed ID: 9457145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
    Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
    Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observations on the effects of buprenorphine and methadone on illicit drug use.
    Pesce AJ; Tran K; Krock K; Cua A; Thomas R
    J Opioid Manag; 2024; 20(3):193-195. PubMed ID: 39017611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.
    Oliveto AH; Feingold A; Schottenfeld R; Jatlow P; Kosten TR
    Arch Gen Psychiatry; 1999 Sep; 56(9):812-20. PubMed ID: 12884887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS.
    Marin SJ; McMillin GA
    Methods Mol Biol; 2016; 1383():69-78. PubMed ID: 26660175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine naloxone concentration at different phases of buprenorphine maintenance treatment.
    Heikman P; Häkkinen M; Gergov M; Ojanperä I
    Drug Test Anal; 2014 Mar; 6(3):220-5. PubMed ID: 23512803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine versus methadone maintenance for opioid dependence.
    Kosten TR; Schottenfeld R; Ziedonis D; Falcioni J
    J Nerv Ment Dis; 1993 Jun; 181(6):358-64. PubMed ID: 8501457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.